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Salubrinal is an agent that reduces the stress to the endoplasmic reticulum by inhibiting de-
phosphorylation of eukaryotic translation initiation factor 2 alpha (eIF2a). We and others have previ-
ously shown that the elevated phosphorylation of eIF2a stimulates bone formation and attenuates bone
resorption. In this study, we applied salubrinal to a mouse model of osteogenesis imperfecta (Oim), and
examined whether it would improve Oim's mechanical property. We conducted in vitro experiments
using RAW264.7 pre-osteoclasts and bone marrow derived cells (BMDCs), and performed in vivo
administration of salubrinal to Oim (þ/) mice. The animal study included two control groups (wildtype
and Oim placebo). The result revealed that salubrinal decreased expression of nuclear factor of activated
T cells cytoplasmic 1 (NFATc1) and suppressed osteoclast maturation, and it stimulated mineralization of
mesenchymal stem cells from BMDCs. Furthermore, daily injection of salubrinal at 2 mg/kg for 2 months
made stiffness (N/mm) and elastic module (GPa) of the femur undistinguishable to those of the wildtype
control. Collectively, this study supported salubrinal's beneﬁcial role to Oim's femora. Unlike
bisphosphonates, salubrinal stimulates bone formation. For juvenile OI patients who may favor
strengthening bone without inactivating bone remodeling, salubrinal may present a novel therapeutic
option.
© 2016 The Authors. Production and hosting by Elsevier B.V. on behalf of Japanese Pharmacological
Society. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).1. Introduction
Osteogenesis Imperfecta (OI) is a rare bone disorder, charac-
terized by brittle bone prone to fracture (1,2). There are at least 8
types of OI (types IeVIII). The majority of affected persons
(85e90%) have mutations in the COL1A1 and COL1A2 genes (type I
collagen genes) (3,4). The incidence of OI is estimated to be one per
20,000 live births, and a high rate of bony fracture occurs mostly in
childhood (5). With adaptive equipment such as metal rods,
wheelchairs, splints etc., many individuals withmoderate/severe OIcology, School of Dentistry,
kusa-Ku, Nagoya 464-8650,
ra).
rmacological Society.
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d/4.0/).can obtain a certain degree of autonomy. Existing drugs such as
bisphosphonates for treating osteoporosis are shown to partially
alleviate OI symptoms (6). However, bisphosphonates do not
stimulate bone formation (7,8). They induce side effects such as
gastrointestinal irritation/ulcer (when given orally), uveitis (eye
inﬂammation), and hypocalcemia (9). Inhibition of receptor acti-
vator of nuclear factor kappa-B ligand (RANKL) by neutralizing
antibody is reported to improve geometric and biomechanical
properties of bone in juvenile OI mice, but it did not decrease
fracture incidence (10). Thus, there is a pressing need to develop a
novel treatment strategy, in particular, using drugs that can in-
crease mechanical properties (11,12).
Since OI is induced by genetic mutations that lead to protein
misfolding (13), we focused in this study on a signaling pathway
linked to protein misfolding, by inhibiting de-phosphorylation of
eIF2a (eukaryotic translation initiation factor 2 alpha). Protein
misfolding, induced by a genetic mutation in type I collagen gene, isnese Pharmacological Society. This is an open access article under the CC BY-NC-ND
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apoptosis of bone-forming osteoblasts (14,15). The elevation of
phosphorylated eIF2a is shown to alleviate protein misfolding re-
sponses, and a synthetic compound, salubrinal (479.8 Da;
C21H17Cl3N4OS), is known to elevate the phosphorylation level of
eIF2a by suppressing protein phosphatase 1, a speciﬁc phosphatase
to eIF2a (16).
We have previously shown that salubrinal is able to inhibit
development of bone-resorbing osteoclasts by in-activating NFATc1
transcription factor (17,18), and stimulate development of bone-
forming osteoblasts by activating ATF4 transcription factor (17,19).
Furthermore, it is reported that salubrinal-driven upregulation of
ATF4 increases osteocalcin (17). Currently, few existing drugs for
treatment of osteoporosis are able to function both as bone-
forming and resorption-inhibitory agents. Neutralizing antibody
to RANKL and bisphosphonates may block bone resorption but they
do not stimulate bone formation. PTH (parathyroid hormone) may
stimulate bone formation, but it does not inhibit bone resorption
(20,21) and has a black box warning prohibiting use in children.
In this study, we used an established pre-osteoblast line, pri-
mary bone marrow derived cells (BMDCs), and the mouse model of
osteogenesis imperfecta (Oim mice), and evaluated the effect of
salubrinal on development of osteoclasts and osteoblasts as well as
mechanical properties of the femur of Oim mice.2. Materials and methods
2.1. Cell culture
RAW264.7 pre-osteoclasts, as well as mouse bone marrow
derived cells isolated from the femur and tibia of wildtype mice,
were cultured in aMEMwith 10% FBS and antibiotics. Furthermore,
mouse bone marrow derived cells (MBMCs) were harvested from
Oim mice, and mesenchymal stem cells were isolated for culture.
They were grown in an osteogenic medium (100 mM ascorbic acid,
and 2 mM beta glycerol phosphate) for 4 weeks. The effect of
salubrinal on mineralization was evaluated using Alizarin red S
staining (Sigma, St. Louise, MO, USA). Salubrinal (R&D systems,
Minneapolis, MN, USA) was given to those cells at a dose of 5 or
10 mM. Salubrinal's concentration of 10 mM in vitro was selected
based on its efﬁcacy as a regulator of eIF2a phosphorylation as well
as non-toxicity to the cells in this study.2.2. qPCR and Western blotting
Reverse transcription was conducted using total RNA and a high-
capacity cDNA reverse transcription kit (Applied Biosystems, Carls-
bad, CA, USA). Quantitative real-time PCR was performed using Po-
wer SYBR green PCR master mix kits (Applied Biosystems). The
mRNA level of NFATc1 was determined with GAPDH as an internal
control. The PCR primers were: NFATc1 (50-GGTGCTGTCTGGCCA-
TAACT-30, 50-GCGGAAAGGTGGTATCTCAA-30); and GAPDH (50-
TGCACCACCAACTGCTTAG-30 and 50-GGATGCAGGGATGATGTTC-30).
Western blotting was conducted using 10e12% SDS gels and
PVDF transfer membranes (Millipore, Billerica, MA, USA). Protein
samples were isolated using a RIPA buffer. We used primary anti-
bodies speciﬁc to eIF2a and p-eIF2a (Cell Signaling, Danvers, MA,
USA), NFATc1 (Santa Cruz Biotechnology, Santa Cruz, CA, USA), as
well as a secondary antibody conjugated with horseradish peroxi-
dase (Cell Signaling). The level of proteins was detected using a
SuperSignal west femto maximum sensitivity substrate (Thermo
Scientiﬁc, Waltham, MA, USA), and the level of b-actin (Sigma) was
employed as a control.2.3. Osteoclastogenesis and TRAP (tartrate-resistant acid
phosphatase) staining
RAW264.7 cells were cultured for 4 days in a 96-well plate
(0.5  104 cells/well) with 50 ng/ml recombinant murine receptor
activator of nuclear factor kappa-B ligand (RANKL; PeproTech,
Rocky Hills, NC, USA) in the presence and absence of 10 mM salu-
brinal. Mouse bone marrow derived cells were cultured with 10 ng/
ml of a recombinant murine macrophage colony-stimulating factor
(M-CSF; PeproTech) for 3 days in 12-well plates. The surface-
attached cells were then used as osteoclast precursors. These pre-
cursors were cultured with 10 ng/ml M-CSF and 50 ng/ml RANKL in
the presence and absence of 10 or 20 mM salubrinal (18). TRAP
staining was conducted using an acid phosphatase leukocyte kit
(Sigma) (18). The number of TRAP-positive cells containing three or
more nuclei was determined.
2.4. Alizarin red S staining
BMDCs, grown in the osteogenic medium, were washed with
PBS twice and ﬁxed with 60% isopropanol for 1 min at room tem-
perature, followed by rehydration with distilled water for 3 min.
Theywere then stainedwith 1% Alizarin red S for 3min andwashed
with distilled water (17).
2.5. Administration of salubrinal to Oim mice
This study employed 32 female mice in total (6 weeks, ~20 g;
Jackson Laboratory, Bar Harbor, ME, USA), including 12 wildtype
mice (B6C3Fe/J) and 20 Oim mice (þ/; B6C3Fe a/a-Col1a2OIM/J).
Oim mice have a spontaneous mutation in the pro-alpha2 chain of
type I collagen. All procedures performed in this study were
approved by the Indiana University Animal Care and Use Com-
mittee and were in compliance with the Guiding Principles in the
Care and Use of Animals endorsed by the American Physiological
Society. Four to ﬁve mice were housed together in a cage. Animals
were fed with standard laboratory chow and water ad libitum, and
they were allowed to acclimate for 1 week before experimentation.
Three animal groups were used, in which Group 1 consisted of 12
wildtype mice as a normal control. Groups 2 and 3 employed 9 and
11 Oim mice as a placebo control and salubrinal administration,
respectively. Mice in group 3 received daily subcutaneous admin-
istration of salubrinal at a dose of 2 mg/kg. This dose was chosen
based on a separate study using a mouse model of postmenopausal
osteoporosis (data unpublished). Mice in group 2 (placebo control)
received daily injection of the vehicle. After mice were euthanized,
the right femur of each mouse was harvested, stripped of soft tis-
sue, wrapped in phosphate buffered saline (PBS)-soaked gauze and
frozen at 20 C until needed.
2.6. Dual-energy X-ray absorptiometry (DEXA), micro computed
tomography (mCT) and mechanical testing
Prior to sacriﬁcing animals (16 weeks old), we conducted
radiographic measurements of the femur, tibia, humerus, ulna, and
lumber spine (lumber) using a Lunar PIXImus device (GE Medical
Systems, Fitchburg, WI, USA). After sacriﬁcing animals, mCT imaging
of the femur was conducted using a high-resolution mCT system
(Bruker-MicroCT, Kontich, Belgium; Skyscan 1172). Scans were
performed on hydrated bones with the long axis oriented vertically
at an isotropic voxel size of 9.9 mm resolution (V ¼ 60 kV,
I ¼ 167 mA), then reconstructed for cortical analysis. After recon-
struction, the scans were uniformly rotated to ensure proper
alignment (Dataviewer, Bruker-MicroCT). After scanning, bones
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Fig. 1. Downregulation of NFATc1 by salubrinal in RAW264.7 pre-osteoclasts and bone marrow derived cells. We cultured RAW264.7 pre-osteoclasts with 50 ng/ml RANKL and
10 mM salubrinal for 1, 2, and 4 days, while bone marrow derived cells with 50 ng/ml RANKL and 10 or 20 mM salubrinal for 2 days. (A) Salubrinal-driven decrease in NFATc1 mRNA
level in response to RANKL stimulation in RAW264.7 pre-osteoclasts. The mRNA level is normalized using the level for the control sample on day 1. (B & C) Elevation of the protein
level of p-eIF2a and reduction in the protein level of NFATc1 by salubrinal in RAW264.7 pre-osteoclasts. The relative expression level is deﬁned as the ratio of the level for the
(RANKL þ Sal) group to the level for the RANKL group, and it is normalized by the ratio on day 1. (D) Reduction in the protein level of NFATc1 by 10 or 20 mM salubrinal in bone
marrow derived cells.
S. Takigawa et al. / Journal of Pharmacological Sciences 132 (2016) 154e161156were wrapped in PBS-soaked gauze and stored at 20 C until
mechanical testing.
All femora were brought to room temperature and then placed
in a four-point bending ﬁxture with the mid-diaphysis positioned
halfway between the loading points (support span of 9mm, loading
span of 3 mm). With the anterior surface in tension, each bone wasmonotonically tested to failure in displacement control at
0.025 mm/s (ElectroForce 3200, TA Instruments, New Castle, DE).
The distance from the distal end of the bone to the location of
fracture initiation was measured using calipers. Seven transverse
slices were obtained from mCT images at the location of fracture and
geometric properties (moment of inertia about the medial-lateral
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Fig. 2. Salubrinal-driven inhibition of osteoclast development in RAW264.7 pre-osteoclasts and bone marrow derived cells. We cultured RAW264.7 pre-osteoclasts with 50 ng/ml
RANKL and 10 mM salubrinal for 4 days, and bone marrow derived cells with 50 ng/ml RANKL and 10 or 20 mM salubrinal for 2 days. (A) Reduction in TRAP staining by salubrinal in
RAW264.7 pre-osteoclasts. The double asterisk indicates p < 0.01. We used 50 ng/ml RANKL without salubrinal as a control. (B) Suppression of osteoclast maturation by salubrinal in
RAW264.7 pre-osteoclasts. (C) Reduction in TRAP staining by 10 or 20 mM salubrinal in bone marrow derived cells. (D) Suppression of osteoclast maturation by salubrinal in bone
marrow derived cells. Of note, DMSO was employed as a vehicle control.
S. Takigawa et al. / Journal of Pharmacological Sciences 132 (2016) 154e161 157centroidal axis and the distance from the centroid to the extreme
ﬁber in tension) were used to map load-displacement into stress-
strain. Pre- and post-yield mechanical properties were obtained
from the resulting data using a custom MATLAB script.
2.7. Statistical analysis
Three to four independent experiments were conducted, and
data were expressed as mean ± S.D. Statistical signiﬁcance was
evaluated using ANOVA followed by post-hoc Tukey test.
3. Results
3.1. Salubrinal-driven downregulation of NFATc1 in RAW264.7 pre-
osteoclasts and bone marrow derived cells
NFATc1 is a key transcription factor for activating development
of osteoclasts. In response to RANKL stimulation, the mRNA level ofNFATc1 was elevated 2e4 fold on days 1e4. Treatment with 10 mM
salubrinal signiﬁcantly suppressed RANKL-induced upregulation of
NFATc1 mRNA on days 2 and 4 in RAW264.7 pre-osteoclasts
(Fig. 1A). Consistent with the role of salubrinal as an inhibitor of
de-phosphorylation of eIF2a, the phosphorylation level of eIF2a
was elevated on days 2 and 4 in RAW264.7 pre-osteoclasts (Fig. 1B
& C). Furthermore, consistent with its mRNA level the NFATc1
protein level was also suppressed on day 4 in RAW264.7 pre-
osteoclasts (Fig. 1B). Furthermore, the level of NFATc1 protein in
bone marrow derived cells was suppressed on day 2 (Fig. 1D).3.2. Inhibition of osteoclast maturation by salubrinal
Besides suppression of NFATc1 expression, salubrinal reduced
TRAP staining and reduced maturation of RAW264.7 pre-
osteoclasts and bone marrow derived cells (Fig. 2). The number of
TRAP-positive multi-nucleated cells was increased by RANKL, and
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To evaluate the role of salubrinal in development of mesen-
chymal stem cells, we harvested BMDCs from Oim mice and
mesenchymal stem cells were incubated in an osteogenic medium
for 4 weeks. The level of alizarin red S staining was elevated by 5 or
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Radiographic measurements by DEXA for the control OI mice
and salubrinal-treated OI mice showed that no signiﬁcant differ-
ence was detectable in bone mineral density (BMD) in the femur,
tibia, humerus, ulna, and spine (Fig. 4A). Furthermore, among three
groups including the wildtype (WT) group, we did not detect clear
differences in the trabecular bone thickness and tissue mineral
density, as well as the cortical bone thickness and tissue mineral
density in mCT images (Fig. 4BeE).0
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In response to a ramp input of force, the forceedisplacement
curve was plotted and the stressestrain relationship was built for
the normal wildtype, Oim placebo, and salubrinal-treated Oim
groups (schematically shown in Fig. 5). These curves qualitatively
show that wildtype bones were the stiffest and strongest with the
greatest ductility, while the Oim placebo group had the lowest0
5
10
15
20
25
30
A
liz
ar
in
 re
d 
S
 s
ta
in
in
g 
(%
) Oim +/-
salubrinal (μM)
**
0                          5                        10
A
B
0 μM                       5 μM                    10 μM
salubrinal concentration 
Fig. 3. Salubrinal-driven elevation of alizarin red S staining in bone marrow derived
mesenchymal cells, which were isolated from heterozygous Oim mice. We cultured
cells using the protocol previously developed for promoting osteoblastogenesis with
0 (control), 5, and 10 mM salubrinal for 28 days. (A) Alizarin red S staining in response
to 0 (control), 5 and 10 mM salubrinal. (B) Quantiﬁcation of the level of alizarin red S
staining. We used 0 mM salubrinal as a control. The double asterisk indicates p < 0.01.
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Fig. 4. Radiographic measurements. (A) Bone mineral density of the femur, tibia, hu-
merus, ulna, and spine (L1-6) using DEXA. We used Oim placebo as a control. (B & C)
Thickness and tissue mineral density of the trabecular bone using mCT. We used
wildtype as a control. (D & E) Thickness and tissue mineral density of the cortical bone
using mCT. We used wildtype as a control.mechanical parameters. Treatment with salubrinal tended to
beneﬁcially impact all mechanical properties in the Oim mice.
From the responses illustrated in Fig. 5, 16 mechanical param-
eters were determined to evaluate the effects of salubrinal
(Table 1). Among them, 2 parameters are linked to force (yield
force, and ultimate force), 3 parameters to displacement
(displacement to yield, post yield displacement, and total
displacement), 3 parameters to energy (work to yield, post yield
work, and total work), 2 parameters to strain (strain to yield, and
total strain), 2 parameters to stress (yield stress, and ultimate
stress), and 4 other parameters (stiffness, elastic modulus, resil-
ience, and toughness). In all parameters, the Oim placebo group
exhibited a lower value than the normal wildtype group (8 of these
reached signiﬁcance). In 15 out of 16 parameters except for post
yield displacement, the salubrinal-treated group showed a higher
value than the Oim placebo group. In 3 parameters (stiffness, elastic
modulus, and total strain), the Oim placebo group means were
signiﬁcantly decreased relative to the wildtype group, and these
differences were abolished by treatment with salubrinal (Fig. 6).
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Fig. 5. Schematic representation of the mechanical responses of the femur in three
animal groups. Each point represents the mean for each group (e.g., mean yield force
and displacement to yield). The error bars are the standard error of the mean (SEM). Of
note, WT Veh ¼ normal wildtype control, OI Veh ¼ Oim placebo control, and OI
Sal ¼ Oim treated with salubrinal. We used wildtype as a control. (A) Relationship
between force (N) and displacement (mm). (B) Relationship between stress (MPa) and
strain (mstrain).
Table 1
Mechanical parameters for three animal groups.
Parameter Unit Normal wildtype Oim placebo
mean ± S.D. mean ± S.D.
Yield force N 16.37 ± 3.16 12.95 ± 4.44
Ultimate force N 24.85 ± 1.54 18.80 ± 4.25
Displacement to yield mm 152.00 ± 24.44 142.67 ± 30.46
Post yield displacement mm 313.67 ± 206.42 141.89 ± 102.33
Total displacement mm 465.67 ± 209.11 284.56 ± 84.44
Stiffness N/mm 119.18 ± 12.30 97.15 ± 15.59
Work to yield mJ 1.33 ± 0.38 1.03 ± 0.49
Post yield work mJ 6.40 ± 3.69 2.38 ± 1.72
Total work mJ 7.73 ± 3.57 3.40 ± 1.67
Yield stress MPa 93.23 ± 16.15 75.53 ± 25.30
Ultimate stress MPa 141.86 ± 8.15 109.83 ± 26.52
Strain to yield mstrain 26,771 ± 4810 26,637 ± 5648
Total strain mstrain 82,851 ± 40,983 53,423 ± 16,646
Modulus GPa 3.87 ± 0.42 3.06 ± 0.64
Resilience MPa 1.34 ± 0.37 1.11 ± 0.51
Toughness MPa 7.94 ± 4.16 3.70 ± 1.80
Dpw: %difference of the mean values ([Oim placebo  normal wildtype]/normal wildtyp
Dsp: %difference of the mean values ([salubrinal-treated Oim  Oim placebo]/normal w
* Statistically signiﬁcant p-value with respect to the normal wildtype.
S. Takigawa et al. / Journal of Pharmacological Sciences 132 (2016) 154e161 1594. Discussion
This study shows that daily administration of salubrinal to
heterozygous Oim mice provides an overall tendency to improve
mechanical properties of the femur of Oim mice. In 15 mechanical
parameters out of 16 parameters in Table 1, the salubrinal-treated
group showed the higher value than the Oim placebo group. In
particular, the Oim placebo group exhibited a signiﬁcantly lower
value in stiffness and elastic modulus than the normal control
group, while no signiﬁcant difference in those values was observed
between the normal control and salubrinal-treated Oim groups.
The salubrinal-treated group presented the highest value in 5 pa-
rameters such as displacement to yield, work to yield, yield stress,
strain to yield, and resilience, although none of those parameters
showed statistical signiﬁcance to the wildtype and Oim control
groups at p < 0.05.
The current study together with our previous works on osteo-
blasts and osteoclasts support the notion that salubrinal's action is
mediated by eIF2a signaling via the responses to the stress to the
endoplasmic reticulum or protein misfolding. Protein misfolding
due to collagen mutation could induce the stress to the endo-
plasmic reticulum and lead to osteoblast apoptosis (14,15). Salu-
brinal-driven elevation of phosphorylated eIF2a translationally
activates the expression of ATF4, which is one of the three known
transcription factor for bone formation (17). Furthermore, we have
previously shown that downregulation of NFATc1, a master tran-
scription factor for osteoclast development, is mediated by sup-
pression of c-fos via eIF2a signaling (18). The reduction in NFATc1's
protein level was steeper than that in its mRNA level. In addition to
salubrinal's transcriptional regulation, this differential reduction
might be linked to its translational regulation via eIF2a phosphor-
ylation. Further analysis is necessary for a better understanding of
salubrinal's action on NFATc1.
Unlike an anabolic agent such as PTH and BMPs that may pre-
sent a potential risk of inducing tumors, salubrinal is shown to
alleviate malignant phenotypes of chondrosarcoma (22) and
mammary tumors (23). Furthermore, salubrinal activates bone
remodeling as opposed to bisphosphonates acting as a suppressor
of bone remodeling. Recent meta-analyses in 2008 and 2014 did
not support a statistically signiﬁcant effect of bisphosphonates on
fractures in osteogenesis imperfecta (24,25). Bisphosphonate
driven inhibition of osteoclasts without stimulating bone formationOim salubrinal
Dpw (%) p* mean ± S.D. Dsp (%) p*
20.9 15.84 ± 3.09 17.7
24.3 20.50 ± 3.89 6.8
6.1 160.55 ± 13.55 11.8
54.8 0.019 138.64 ± 62.80 1.0 0.016
38.9 0.009 299.18 ± 70.68 3.1 0.018
18.5 0.005 106.31 ± 15.76 7.7
22.6 1.34 ± 0.34 23.3
62.8 0.002 2.59 ± 1.30 3.3 0.003
56.0 0.001 3.94 ± 1.54 7.0 0.002
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22.6 120.90 ± 11.31 7.8
0.5 28,577 ± 4480 7.2
35.5 0.043 55,450 ± 16,132 2.4
20.9 0.004 3.47 ± 0.53 10.6
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S. Takigawa et al. / Journal of Pharmacological Sciences 132 (2016) 154e161160may lead to non-dynamic bone, in which microcracks are often not
repaired (26). An additional potential beneﬁt with salubrinal is its
effects on cartilage, which needs to be protected from degradation
without excessive bone formation. Salubrinal is able to protect
cartilage degradation by suppressionMMP13 activity (27,28). These
suppressive effects on tumor growth and skeletal inﬂammation are
salubrinal's unique features.
The Oim mouse model in this study exhibited a clear trend of
weakened mechanical properties, but the statistically signiﬁcant
difference was not detected in the half of the selected parameters.
The subtle differences between the normal wildtype and Oim (þ/)
mice made it difﬁcult to identify signiﬁcant efﬁcacy in salubrinal's
administration to Oim (þ/) mice. Consistent with our observation,
no signiﬁcant difference in bone volume is reported between the
normal wildtype and Oim (þ/) mice (29). Since Oim (/) mice
present a more severe phenotype than Oim (þ/) mice, employing
Oim (/) mice and examining their responses to salubrinal might
be the next step. Alternatively, different methodologies such as
Raman spectroscopy might be useful to detect subtle differences
among groups. Taken together, salubrinal might potentiallyameliorate Oim's damaged collagen ﬁbrils, since it is reported that
anti-sclerostin antibody, which promotes bone formation, alters
bone quality (30).
Although all patients with OI present brittle bone, the genetic
cause of OI differs. The murine model of OI, employed in this study,
correspond to type I collagen mutation, the most frequent type of
OI. Among other types of OI, types VeX are caused by mutations in
IFITM5 (interferon induced transmembrane protein 5), SERPINF1
(serpin peptidase inhibitor 1), CRTAP (cartilage associated protein),
LEPRE1 (leucine proline-enriched proteoglycan 1), PPIB (peptidyl
prolyl cis-trans isomerase B), and SERPINH1 (serpin family H
member 1), respectively (26). Therapeutic efﬁcacy of any agent
should vary depending on OI types and it is recommended to
further evaluate the effects of salubrinal for other types of OI.
In this study, we employed a single dose of 2 mg/kg body weight
via subcutaneous injection. It is possible that other doses at
different routes and treatment durations may provide superior ef-
ﬁcacy in improving bone quality and quantity. In summary, this
study demonstrated a novel strategy for potential treatment of OI
with salubrinal via regulation of eIF2a phosphorylation. The effect
of salubrinal should be test on other forms of OI since the role of
eIF2a signalingmay differ depending on genes and regulatory steps
in collagen mutation.Conﬂicts of interest
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